The colloids (blood plasma) market represents a critical segment of the global intravenous (IV) fluid therapy industry. Colloids are plasma volume expanders used extensively in clinical settings to manage hypovolemia, shock, trauma, burns, and major surgeries. These solutions contain large molecules such as albumin, gelatins, dextrans, and hydroxyethyl starch that remain in the vascular compartment, helping maintain oncotic pressure and improve circulatory stability. Rising hospitalization rates, increasing surgical procedures, and growing awareness of advanced fluid management protocols are driving steady demand for colloids across healthcare systems worldwide.
According to Straits Research, the market has shown consistent growth due to expanding critical care infrastructure and increased use of colloids in emergency medicine and intensive care units. Developing economies are witnessing rapid adoption owing to improved healthcare access and higher government healthcare expenditure.
Market Size 2024 – USD 3.43 Billion. • Market Size 2025 – USD 3.64 Billion. • Market Size 2033 – USD 5.56 Billion. • CAGR (2025–2033) – 5.3%.
Get Your Sample Report Here: https://straitsresearch.com/report/colloids-blood-plasma-market
Market Drivers
Rising Surgical and Trauma Cases
The growing number of surgical interventions, road accidents, and trauma cases globally is a major driver for the colloids (blood plasma) market. Colloids are frequently used in perioperative care and trauma resuscitation due to their rapid plasma volume expansion capability, which supports hemodynamic stability during critical procedures.
Expansion of Critical Care and Emergency Services
The expansion of intensive care units, emergency departments, and advanced trauma centers is increasing the demand for colloids. With more hospitals adopting evidence-based fluid resuscitation protocols, colloids continue to play a vital role in managing critically ill patients.
Increasing Prevalence of Chronic and Lifestyle Diseases
Chronic diseases such as cardiovascular disorders, renal diseases, and liver conditions often require surgical or intensive care interventions. This indirectly boosts the use of colloids for volume replacement and shock management, supporting long-term market growth.
Download Your Sample Report Now@ https://straitsresearch.com/report/colloids-blood-plasma-market/request-sample
Market Challenges
Safety Concerns and Regulatory Scrutiny
Certain synthetic colloids have faced scrutiny due to concerns over renal complications and coagulation effects. Regulatory restrictions and clinical guidelines limiting the use of specific colloids may restrain market growth in some regions.
Availability of Alternatives
Crystalloids are often preferred as first-line therapy due to lower cost and fewer side effects. The increasing preference for balanced crystalloids in some clinical guidelines poses a challenge to the widespread adoption of colloids.
Market Segmentation Analysis
By Product Type
The market is segmented into albumin, hydroxyethyl starch, gelatin, and dextran. Albumin holds a significant share due to its natural origin, high safety profile, and extensive use in critical care, liver diseases, and burn management. Synthetic colloids such as hydroxyethyl starch and gelatins are used for short-term volume expansion, particularly in surgical settings.
By Application
Based on application, the market includes hypovolemia, shock, burns, surgery, and other medical uses. Hypovolemia and shock management account for a major portion of demand, driven by trauma cases and emergency admissions. Surgical applications are also growing steadily due to the rise in elective and minimally invasive surgeries worldwide.
By End User
Hospitals dominate the end-user segment, followed by specialty clinics and ambulatory surgical centers. Hospitals remain the primary consumers due to the high volume of critical care patients and availability of advanced infrastructure for IV fluid administration.
By Region
North America leads the global market due to advanced healthcare systems, high adoption of critical care protocols, and strong presence of leading manufacturers. Europe follows closely with established clinical guidelines and high healthcare spending. Asia-Pacific is expected to witness the fastest growth owing to expanding healthcare infrastructure, rising medical tourism, and increasing awareness of advanced fluid therapies.
Buy the Full Colloids (Blood Plasma) Market Research Report for In-Depth Insights and Strategic Intelligence Here: https://straitsresearch.com/buy-now/colloids-blood-plasma-market
Competitive Landscape and Top Players Analysis
The colloids (blood plasma) market is moderately consolidated, with key players focusing on product innovation, regulatory approvals, and strategic partnerships to strengthen their market presence. According to Straits Research, major companies include:
Grifols S.A. – A leading plasma-derived products manufacturer with a strong portfolio of albumin and plasma solutions, serving hospitals and critical care centers globally.
CSL Limited – Renowned for its plasma fractionation expertise, CSL offers high-quality albumin products widely used in intensive care and surgical settings.
Octapharma AG – Specializes in human protein products, including albumin solutions, with a strong distribution network across Europe and emerging markets.
Takeda Pharmaceutical Company Limited – Through its plasma-derived therapies division, the company provides advanced colloid solutions for critical care and specialty applications.
Fresenius Kabi AG – A major provider of infusion therapies, including synthetic colloids, with a focus on hospital-based care and perioperative management.
These players emphasize research and development, quality assurance, and geographic expansion to meet rising global demand.
Conclusion
The global colloids (blood plasma) market is poised for steady growth, supported by rising critical care needs, increasing surgical volumes, and expanding healthcare infrastructure worldwide. While safety concerns and competition from alternatives remain challenges, continuous advancements in plasma-derived therapies and growing demand from emerging economies are expected to sustain market momentum through 2033.
About Us
Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.
